AMRS:NSD-Amyris Inc (USD)

COMMON STOCK | Specialty Chemicals | NSD

Last Closing Price

USD 2.29

Change

-0.03 (-1.29)%

Market Cap

USD 0.74B

Volume

0.01B

Avg Analyst Target

USD 2.50 (+9.17%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AMRS Stock Forecast & Price:
Based on the Amyris Inc stock forecasts from 2 analysts, the average analyst target price for Amyris Inc is USD 2.50 over the next 12 months. Amyris Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Amyris Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Amyris Inc’s stock price was USD 2.29. Amyris Inc’s stock price has changed by +20.53% over the past week, -0.43% over the past month and -84.77% over the last year.

About Amyris Inc (AMRS:NSD)

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Specialty Chemicals

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BCPC Balchem Corporation

-2.56 (-2.00%)

USD4.11B 38.35 22.87
WDFC WD-40 Company

-1.77 (-0.95%)

USD2.54B 42.07 28.76
IOSP Innospec Inc

+0.61 (+0.64%)

USD2.38B 20.57 12.02
GPRE Green Plains Renewable Energy ..

+0.09 (+0.24%)

USD2.19B 40.40 36.96
LWLG Lightwave Logic Inc

-0.29 (-2.82%)

USD1.15B N/A -67.19
HWKN Hawkins Inc

-0.32 (-0.76%)

USD0.85B 16.45 9.96
GEVO Gevo Inc

+0.13 (+4.02%)

USD0.76B 0.30 -8.32
HDSN Hudson Technologies Inc

+0.25 (+2.73%)

USD0.40B 4.28 3.89
ALTO Alto Ingredients Inc

-0.06 (-1.24%)

USD0.35B 8.65 5.49
LOOP Loop Industries Inc

-0.02 (-0.31%)

USD0.31B N/A -5.71

ETFs Containing AMRS

Symbol Name Weight Mer Price(Change) Market Cap
CBDX:LSE The Medical Cannabis and .. 0.00 % 0.80 %

-0.16 (-2.55%)

N/A
FLWG:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-8.58 (-2.96%)

N/A
FLWR:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-0.11 (-3.15%)

N/A
BLUM:XETRA Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

-0.12 (-3.37%)

USD0.02B
CBSX:XETRA The Medical Cannabis and .. 0.00 % 0.80 %

-0.16 (-2.72%)

USD0.02B
BLUM:F Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

N/A
CBSX:F Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Specialty Chemicals)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.67% 18% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.67% 18% F 19% F
Trailing 12 Months  
Capital Gain -84.40% 12% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.40% 12% F 9% F
Trailing 5 Years  
Capital Gain -14.87% 23% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.87% 23% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain 71.94% 82% B- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.94% 82% B- 93% A
Risk Return Profile  
Volatility (Standard Deviation) 184.89% 24% F 6% F
Risk Adjusted Return 38.91% 47% F 71% C-
Market Capitalization 0.74B 59% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Specialty Chemicals)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.00 29% F 31% F
Price / Cash Flow Ratio -4.09 76% C 68% D+
EV/EBITDA -20.51 88% B+ 90% A-
Management Effectiveness  
Return on Equity -532.08% 12% F 3% F
Return on Invested Capital -101.37% 25% F 11% F
Return on Assets -39.07% 29% F 8% F
Debt to Equity Ratio N/A 10% F 0% N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 10.07 24% F 8% F
Short Percent 21.61% 12% F 7% F
Beta 1.63 38% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector